Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Merchant

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Science Translational Medicine|February 8, 2013
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancerGanapati V Hegde, Cecile C de la Cruz, Cecilia Chiu, et al.
NPJ Precision Oncology|June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer typesMarie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Cell Reports|February 9, 2022
CRAF dimerization with ARAF regulates KRAS-driven tumor growthAvinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Journal of Medicinal Chemistry|March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase InhibitorMalcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
Cancer Discovery|September 5, 2020
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint BlockadeFrederick J Kohlhapp, Dipica Haribhai, Rebecca Mathew, et al.
Analytical Chemistry|March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass SpectrometryJohn C Tran, Thomas Hunsaker, Christina Bell, et al.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
Nature Immunology|March 22, 2022
Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunityRosa Barreira da Silva, Ricardo M Leitao, Ximo Pechuan-Jorge, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Science Translational Medicine|February 8, 2013
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancerGanapati V Hegde, Cecile C de la Cruz, Cecilia Chiu, et al.
NPJ Precision Oncology|June 7, 2018
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer typesMarie-Claire Wagle, Daniel Kirouac, Christiaan Klijn, et al.
Plos One|October 6, 2017
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Cell Reports|February 9, 2022
CRAF dimerization with ARAF regulates KRAS-driven tumor growthAvinashnarayan Venkatanarayan, Jason Liang, Ivana Yen, et al.
Plos One|January 26, 2018
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumorsMark Merchant, John Moffat, Gabriele Schaefer, et al.
Journal of Medicinal Chemistry|March 29, 2021
Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase InhibitorMalcolm P Huestis, Darlene Dela Cruz, Antonio G DiPasquale, et al.
Cancer Discovery|September 5, 2020
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint BlockadeFrederick J Kohlhapp, Dipica Haribhai, Rebecca Mathew, et al.
Analytical Chemistry|March 6, 2023
Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass SpectrometryJohn C Tran, Thomas Hunsaker, Christina Bell, et al.
Nature Biotechnology|January 7, 2022
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitorsChristopher W Davies, Angela J Oh, Rana Mroue, et al.
Nature Immunology|March 22, 2022
Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunityRosa Barreira da Silva, Ricardo M Leitao, Ximo Pechuan-Jorge, et al.
Pageof 11